Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jaume Ayguasanosa
Observed names:
J Ayguasanosa,
J. Ayguasanosa,
Jaume Ayguasanosa Dachs
Institutions:
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda,
Argenx (Belgium)
Observed institutions:
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda,
Grifols (Spain),
Argenx (Belgium)
ORCID:
0000-0002-6622-0159
Observed ORCID:
0000-0002-6622-0159
OpenAlex ID:
A5066738096
Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial
2023
·
Catherine M Broome
, Vickie McDonald
, et al.
·
The Lancet
·
124
SPARTA clinical trial design: Exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency
2015
·
Susan Sorrells
, Sandra Camprubi
, et al.
·
Respiratory Medicine
·
52
PDF
A Phase 3 Multicenter, Prospective, Open-Label Efficacy and Safety Study of Immune Globulin (Human) 10% Caprylate/Chromatography Purified in Patients with Myasthenia Gravis Exacerbations
2019
·
Guntis Karelis
, Rodica Balasa
, et al.
·
European Neurology
·
30
PDF
A Prospective, Randomized, Phase III Study to Evaluate the Efficacy and Safety of Fibrin Sealant Grifols as an Adjunct to Hemostasis as Compared to Cellulose Sheets in Hepatic Surgery Resections
2018
·
Miloš Bjelović
, Jaume Ayguasanosa
, et al.
·
Journal of Gastrointestinal Surgery
·
23
A prospective, single-blind, randomized, phase III study to evaluate the safety and efficacy of Fibrin Sealant Grifols as an adjunct to hemostasis compared with manual compression in vascular surgery
2019
·
Dragoslav Nenezić
, Jaume Ayguasanosa
, et al.
·
Journal of Vascular Surgery
·
20
PDF
Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: Results of a Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)
2022
·
Catherine M. Broome
, Vickie McDonald
, et al.
·
Blood
·
14
Clinical efficacy and safety of Flebogammadif ® , a new high‐purity human intravenous immunoglobulin, in adult patients with chronic idiopathic thrombocytopenic purpura
2009
·
A. Julia
, L. Kovaleva
, et al.
·
Transfusion Medicine
·
11
Pharmacokinetics, surrogate efficacy and safety evaluations of a new human plasma-derived fibrinogen concentrate (FIB Grifols) in adult patients with congenital afibrinogenemia
2021
·
Cecil Reuben Ross
, Sitalakshmi Subramanian
, et al.
·
Thrombosis Research
·
9
Safety and Efficacy of Intravenous Immunoglobulin (Flebogamma ® 10% DIF) in Patients with Immune Thrombocytopenic Purpura
2018
·
Shashikant Apte
, Jordi Navarro-Puerto
, et al.
·
Immunotherapy
·
8
PDF
Pharmacokinetic modeling and simulation of subcutaneous and intravenous IgG dosing in patients with primary immunodeficiency diseases
2022
·
Graciela Navarro-Mora
, Joan J. Alberti
, et al.
·
International Immunopharmacology
·
7
PDF
Prospective, Randomized, Phase II, Non-Inferiority Study to Evaluate the Safety and Efficacy of Topical Thrombin (Human) Grifols as Adjunct to Hemostasis During Vascular, Hepatic, Soft Tissue, and Spinal Open Surgery
2019
·
Harold Minkowitz
, Jordi Navarro-Puerto
, et al.
·
Journal of the American College of Surgeons
·
7
Effect of Efgartigimod IV on Immature Platelet Count Fraction in Primary Immune Thrombocytopenia
2024
·
Filip Matthijssens
, Yoshitaka Miyakawa
, et al.
·
Blood
·
3
Intravenous Efgartigimod for the Treatment of Primary Immune Thrombocytopenia in Adults: A Planned, Phase 3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Arm Study with Open-Label Period (ADVANCE NEXT)
2024
·
Hanny Al-Samkari
, Vickie McDonald
, et al.
·
Blood
·
2
PDF
S302: Long-term Safety and Efficacy of Efgartigimod in Patients With Primary Immune Thrombocytopenia: Interim Results of the Advance+ Study
2023
·
Monica Carpenedo
, Catherine M Broome
, et al.
·
HemaSphere
·
2
Pb2305: Efgartigimod: Clinical Development of a Novel Fcrn Antagonist in the Treatment of Autoimmune Diseases
2022
·
P. Knoebl
, H. de Haard
, et al.
·
HemaSphere
·
2
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia ( ADVANCE SC ): A Multicenter, Randomized, Double‐Blinded, Placebo‐Controlled, Phase 3 Trial
2026
·
Nichola Cooper
, Catherine M. Broome
, et al.
·
American Journal of Hematology
·
1
Time to Achieve Platelet Count Response after Intravenous Efgartigimod in Adults with Primary Immune Thrombocytopenia: A Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial (ADVANCE IV)
2023
·
Catherine M. Broome
, Vickie McDonald
, et al.
·
Blood
·
1
PDF
SPARTA: Efficacy and safety assessment of two regimens of alpha 1 -proteinase inhibitor in emphysema due to alpha 1 -antitrypsin deficiency
2013
·
Mark Forshag
, Sandra Camprubi
, et al.
·
European Respiratory Journal
·
1
PB1552 Intact COVID-19 Vaccination Response and Overall Safety in Participants from the Phase 3, Multicenter, Double-Blinded, Placebo-Controlled, Randomized Clinical Trial of Intravenous Efgartigimod in ITP (ADVANCE IV)
2026
·
Yoshitaka Miyakawa
, Hanny Al-Samkari
, et al.
·
Research and Practice in Thrombosis and Haemostasis
PDF
OC 25.2 Time to Achieve Platelet Count Response After Intravenous Efgartigimod in Adults With Primary Immune Thrombocytopenia in a Phase 3, Multicenter, Double-blinded, Placebo-controlled, Randomized Clinical Trial (ADVANCE IV) and Its Open-Label Extension Study (ADVANCE IV+)
2026
·
Yoshitaka Miyakawa
, Catherine Broome
, et al.
·
Research and Practice in Thrombosis and Haemostasis
Effect of efgartigimod IV on immature platelet fraction in primary immune thrombocytopenia in the ADVANCE IV trial
2026
·
Hanny Al‐Samkari
, Filip Matthijssens
, et al.
·
British Journal of Haematology
Efgartigimod as a treatment for adults with primary immune thrombocytopenia: a plain language summary of the ADVANCE IV study
2026
·
Catherine Broome
, Yoshitaka Miyakawa
, et al.
·
Therapeutic Advances in Hematology
Long-Term Safety and Efficacy of Efgartigimod in Adults with Primary Immune Thrombocytopenia: Interim Results of the ADVANCE IV+ Phase 3 Trial
2026
·
Monica Carpenedo
, Catherine Broome
, et al.
·
SSRN Electronic Journal
PDF
Sustained improvements in patient-reported outcomes after intravenous efgartigimod in adults with primary immune thrombocytopenia in a Phase 3 clinical trial (ADVANCE IV) and the first 52 weeks in its open-label extension study (ADVANCE IV+)
2025
·
Monica Carpenedo
, Catherine Broome
, et al.
·
Blood
CO13 Evidence Gap Analysis of the Burden of Illness and Treatment of Primary Immune Thrombocytopenia
2022
·
J Yang
, C Masaquel
, et al.
·
Value in Health
Show more works
View as search
Works count:
26
Citation count:
317
H-index:
8
I10-index:
7
Year
Topic
Type